Savara (SVRA) Return on Sales (2013 - 2022)

Savara (SVRA) posted quarterly Return on Sales of 404.17% for Q1 2022, down 24212.83% quarter-over-quarter from 1.66% in Q4 2021.

Savara (SVRA) Return on Sales (2013 - 2022) Analysis & Trends

Savara (SVRA) has reported Return on Sales for 8 consecutive years, with 404.17% the latest figure, recorded in Q1 2022.

In Q1 2022, Return on Sales changed N/A year-over-year to 404.17%; the TTM figure through Mar 2022 stood at 404.17% (changed N/A YoY), while the FY2020 annual figure was 98.03%, changed N/A from the prior year.
Return on Sales retreated to 404.17% in Q1 2022 per SVRA's latest filing, from 1.66% in the prior quarter.
Across five years, Return on Sales topped out at 0.44% in Q3 2020 and bottomed at 24825.92% in Q4 2020.
Historically, Return on Sales has averaged 5066.0% across 3 years, with a median of 97.83% in 2021.
On a YoY basis, Return on Sales climbed as much as 2482426 bps in 2021 and fell as far as 9739 bps in 2021.
Savara's Return on Sales stood at 24825.92% in 2020, then surged by 100 bps to 1.66% in 2021, then tumbled by 24213 bps to 404.17% in 2022.
Business Quant data shows SVRA's Return on Sales at 404.17% in Q1 2022, 1.66% in Q4 2021, and 97.83% in Q3 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	ROS (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	0.00%
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	0.00%
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	0.00%
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	0.00%
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	0.00%
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	0.00%
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	0.00%
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	0.00%
10	Savara	1.11 Bn	1.11 Bn	-	-

Download Data